Ibuprofen and thromboembolism in SARS-COV2

J Thromb Haemost. 2020 Sep;18(9):2425-2427. doi: 10.1111/jth.14901.

Abstract

Recent and developing literature has begun reporting on the incidence of thromboembolic

events associated with COVID‐19. Klok et al. analysed 184 SARS‐CoV2‐positive ICU

patients in two Dutch University Hospitals, reporting an incidence of thrombotic

complications to be 31%, with Pulmonary Embolism (PE) comprising 81% of these complications. [1] Moreover, Cui et al. reports on a population of 81 ICU patients at the Union Hospital, Wuhan, an incidence of 25% in VTE, also possibly related to worse prognosis.[2] Wang et al. collected data from 1026 COVID‐19 positive patients in 31 provincial administrative regions in China and found 40% of the patients as high risk for VTE according to the Padua Prediction Score, with 11% being predicted to go on developing VTE. [3] Other reports and studies have also discussed the role of acute PE in COVID‐19. Recent studies have also reported and advised on the use of prophylactic Low Molecular Weight Heparin (LMWH) in COVID‐19 patients, to prevent the severe outcomes associated with thromboembolic complications.

Publication types

  • Letter

MeSH terms

  • COVID-19*
  • Humans
  • Ibuprofen / adverse effects
  • RNA, Viral
  • SARS-CoV-2
  • Thromboembolism*

Substances

  • RNA, Viral
  • Ibuprofen